Correspondence 0001437749-24-005770 from Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685) (VTGN)
Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685)
Date: Feb. 27, 2024 · CIK: 0001411685 · Accession: 0001437749-24-005770
AI Filing Summary & Sentiment
File numbers found in text: 333-277041
Letter
vtgn20240227_corresp.htm
February 27, 2024
Via EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549-6010
Attention:
Tyler Howes
Re:
Vistagen Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 13, 2024
File No. 333-277041
To the addressees set forth above:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement on Form S-3 so that it will become effective on February 29, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Vistagen Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Scott W. Westhoff of Latham & Watkins LLP, counsel to the Company, at (312) 876-7605, or in his absence, Christopher D. Lueking at (312) 876-7680, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
Vistagen Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm vtgn20240227_corresp.htm February 27, 2024 Via EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-6010 Attention: Tyler Howes Re: Vistagen Therapeutics, Inc. Registration Statement on Form S-3 Filed February 13, 2024 File No. 333-277041 To the addressees set forth above: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement on Form S-3 so that it will become effective on February 29, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Vistagen Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Scott W. Westhoff of Latham & Watkins LLP, counsel to the Company, at (312) 876-7605, or in his absence, Christopher D. Lueking at (312) 876-7680, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. Sincerely yours, Vistagen Therapeutics, Inc. By: /s/ Shawn K. Singh Shawn K. Singh, J.D. Chief Executive Officer cc: Christopher D. Lueking, Esq. Scott W. Westhoff, Esq.